Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Vertex Pharmaceuticals, Inc shares valued at $76,021 were purchased by LR 2019 Benefit Trust on May 21 ’25. At $447.18 per share, LR 2019 Benefit Trust acquired 170 shares.
Also, SR 2019 Benefit Trust purchased 170 shares, netting a total of over 76,021 in proceeds.
Before that, ALTSHULER DAVID had sold 52 shares from its account. In a trade valued at $22,084, the EVP, Chief Scientific Officer traded Vertex Pharmaceuticals, Inc shares for $424.69 each. Upon closing the transaction, the insider’s holdings decreased to 52 shares, worth approximately $10.41 million.
As published in a research note from Wolfe Research on May 07, 2025, Vertex Pharmaceuticals, Inc [VRTX] has been rated down from an Outperform to a Peer perform. Analysts at Leerink Partners downgraded the stock from ‘”an Outperform”‘ to ‘”a Market perform”‘ outlook in a report released in early May. Earlier on February 12, 2025, Canaccord Genuity upgraded its rating. Their new recommendation was “a Hold” for VRTX stock which previously was a “a Sell”.
Analyzing VRTX Stock Performance
During the last five days, there has been a surge of approximately 2.70%. Over the course of the year, Vertex Pharmaceuticals, Inc shares have jumped approximately 11.02%. Shares of the company reached a 52-week high of $519.68 on 03/14/25 and a 52-week low of $397.24 on 01/13/25.
Support And Resistance Levels for Vertex Pharmaceuticals, Inc (VRTX)
According to the 24-hour chart, there is a support level at 443.49, which, if violated, would cause prices to drop to 439.90. In the upper region, resistance lies at 449.95. The next price resistance is at 452.82. RSI (Relative Strength Index) is 46.08 on the 14-day chart, showing neutral technical sentiment.
